Litcius/Paper detail

Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC

Misako Nagasaka, Viola W. Zhu, Sun Min Lim, Michael N. Greco, Fengying Wu, Sai‐Hong Ignatius Ou

2020Journal of Thoracic Oncology216 citationsDOIOpen Access PDF

Topics & Concepts

OsimertinibMedicineThird generationT790MClinical trialOncologyInternal medicineStandard of careAfatinibErlotinibEpidermal growth factor receptorGefitinibCancerComputer scienceTelecommunicationsLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC | Litcius